This reduction is mediated through the AMP-activated protein kinase (AMPK) pathway and Forkhead Box O3 (FOXO3) signaling, as observed in both live rats (in vivo) and hepatoma HepG2 cells cultured in laboratories (in vitro). The gene discussed is FOXO3; the disease is hepatocellular carcinoma.